Asset Prioritization in Pharma Domain: How In-Licensing Led to the Selection of a High-Value Game-Changing Asset for a Pharma Client

PR Newswire06:31

The Zacks Analyst Blog Highlights Cisco Systems, Abbott Laboratories and Coca-Cola

Zacks 02:00

This Is What Whales Are Betting On Abbott Laboratories

Benzinga01:45

Abbott Laboratories: A Significant Addition to Eaton Vance Worldwide Health Sciences Fund

Yahoo Finance01:01

Redburn Atlantic Adjusts Abbott Laboratories Price Target to $130 From $120

MT Newswires00:36 · Ratings

Biological Drugs Strategic Research Report 2024-2030, Profiles of 45+ Players Including Abbott Laboratories, Amgen, Baxter, Biogen, BMS, Eli Lilly and Co, GSK, Merck, Novartis, and Pfizer

Yahoo FinanceJan 27 23:49